Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis
* Maintenance of healing of erosive esophagitis
* Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Gastroesophageal reflux disease (GERD) symptoms
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is 40 mg orally or intravenously twice daily. Doses may be adjusted based on clinical response. Usual doses range from 40 mg to 240 mg daily. Doses > 160 mg daily should be divided and administered every 12 hours.
* **GERD Symptoms:** 20 mg orally once daily for up to 4 weeks.
## Pediatric Dosing
* **GERD Symptoms (5-16 years):** 20 mg orally once daily for up to 4 weeks.
* **Erosive Esophagitis (5-16 years):** 40 mg orally once daily for up to 8 weeks.
* Dosing in younger children is not established.
## Dose Adjustments
No dose adjustment is generally required for renal or hepatic impairment, although caution may be warranted in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence.
Long-term use may be associated with:
* Increased risk of *Clostridioides difficile*-associated diarrhea
* Bone fractures (hip, wrist, spine)
* Vitamin B12 deficiency
* Hypomagnesemia
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors (e.g., atazanavir).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may increase concentrations of drugs metabolized by this enzyme (e.g., clopidogrel, voriconazole).
## Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Consider monitoring magnesium levels in patients on long-term therapy, especially if taking concomitant medications like digoxin or diuretics.
* Monitor for signs of bone fracture risk.
## Clinical Pearls
* Administer pantoprazole 30 minutes before a meal for optimal efficacy.
* Pantoprazole delayed-release tablets should be swallowed whole and not crushed or chewed.
* Long-term PPI use should be re-evaluated regularly to ensure continued need.
* Consider alternatives for patients requiring frequent or high-dose antacids, as PPIs can be less effective in this population.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local guidelines before making clinical decisions.*
